Action on AMD. Optimising patient management: Act now to ensure current and continual delivery of best possible patient care

Eye (Basingstoke)

Volumn 26, Issue , 2012, Pages S2-S21

  Amoaku, W ^a   Blakeney, S ^b   Freeman, M ^c   Gale, R ^d   Johnston, R ^e   Kelly, S P ^f   McLaughlan, B ^g   Sahu, D ^h   Varma, D ⁱ  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b BP Eyecare LTD ^*  (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d York NHS Teaching Hospital Foundation Trust   (United Kingdom)

^e CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^f ROYAL BOLTON HOSPITAL   (United Kingdom)

^g Royal National Institute of Blind People   (United Kingdom)

^h SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

ⁱ SUNDERLAND EYE INFIRMARY   (United Kingdom)

Author keywords

Age related macular degeneration; Anti VEGF therapy; Commissioning; Health care facilities; Manpower; Services

Indexed keywords

PEGAPTANIB; RANIBIZUMAB;

BLINDNESS; CLINICAL NURSE SPECIALIST; CLINICAL PRACTICE; DIABETIC MACULAR EDEMA; ELECTRONIC MEDICAL RECORD; FOLLOW UP; FUNDING; GLAUCOMA; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; INTRAOCULAR PRESSURE; MEDICAL ASSISTANT; MEDICAL DOCUMENTATION; NURSE PRACTITIONER; OPTIC DISK; OPTICAL COHERENCE TOMOGRAPHY; OPTOMETRY; PATIENT CARE; PREVENTIVE HEALTH SERVICE; PRIMARY MEDICAL CARE; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; REVIEW; SLOW RELEASE FORMULATION; TEAMWORK; UNITED KINGDOM; VISUAL ACUITY; WORKLOAD;

EID: 84856609239     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.343     Document Type: Article

References (26)

1. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdon? B J Ophthalmol 2003; 87: 312–317.
2. Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000. Eye 2008; 22: 905–911.
3. NICE Technology Appraisal Guidance TA155. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. 2008. Accessed at http://www.nice.org.uk/nicemedia/pdf/TA155guidance.pdf.
4. Congdon N, O’Colmain B, Klaver CCW, Klein R, Munoz B, Friedman DS et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122: 477–485.
5. Bressler NM, Arnold J, Barbazetto I, Birngruber R, Blumenkranz MS, Bressler SB et al. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol 2001; 119: 198–207.
6. Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes 2006; 4: 97–117.
7. NICE Technology Appraisal Guidance TA68. Photodynamic therapy for age-related macular degeneration. 2003. Accessed at http://www.nice.org.uk/nicemedia/live/11512/32728/32728.pdf.
8. Royal College of Ophthalmologists. Commissioning contemporary AMD services: a guide for commissioners and clinicians. 2007. Accessed at http://www.rcophth. ac.uk/core/core_picker/download. asp?id¼181&filetitle¼ Commissioningþ ContemporaryþAMDþServices.
9. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 1, 57–65e5.
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–1431.
11. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432–1444.
12. Bressler NM, Chang TS, Suner IJ, Fine JT, Dolan CM, Ward J et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye. Ophthalmol 2010; 117: 747–756.
13. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Improved vision-related function after ranibizumab vs photodynamic therapy. Arch Ophthalmol 2009; 127(1): 13–21.
14. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration. Arch Ophthalmol 2007; 125(11): 1460–1469.
15. RNIB. Future Sight Loss UK (1). The economic impact of partial sight and blindness in the UK adult population. 2009. Accessed at http://www.rnib.org.uk/aboutus/Research/reports/2009andearlier/FSUK_Report.pdf.
16. The Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117(6): 1064–1077.
17. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC et al. Ranibizumab for macular edema following branch retinal vein occlusion. Ophthalmology 2010; 117(6): 1102–1112.
18. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al. Ranibizumab for macular edema following central retinal vein occlusion. Ophthalmology 2010; 117(6): 1124–1133.
19. Ocular Surgery News Europe Edition. Growing demand for eye care services may highlight shortage of ophthalmologists in Europe. 2010. Accessed at http://www.osnsupersite.com/view.aspx?rid¼65866.
20. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009; 148(10): 43–58.
21. NICE Clinical Guidelines CG85. Glaucoma. 2009. Accessed at http://www.nice.org.uk/nicemedia/live/12145/43887/43887.pdf.
22. The Scottish Government. Roll-out of IT services for optometry. News release. 2010. Accessed at http://www.scotland.gov.uk/News/Releases/2010/09/27113039.
23. Cameron JR, Ahmed S, Curry P, Forrest G, Sanders R. Impact of direct electronic optometric referral with ocular imaging to a hospital eye service. Eye 2009; 23: 1134–1140.
24. Kelly SP, Wallwork I, Haider D, Qureshi K. Teleophthalmology with optical coherence tomography imaging in community optometry. Evaluation of a quality improvement for macular patients. Clin Ophthal 2011; 5: 1673–1678.
25. Kelly SP, Barua A. A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications. Eye 2011; 25: 710–716.
26. Royal College of Ophthalmologists. AMD Services Survey. Royal College of Ophthalmologists: London, 2009. Accessed at http://www.rcophth.ac.uk/page.asp?section¼295& sectionTitle¼AMDþServicesþSurvey.